LECANEMAB: THE NEW ALZHEIMER’S DRUG Lecanemab (brand name Leqembi) is the first drug that appears to slow the decline of memory and thinking of Alzheimer’s disease. After promising trial test results, the Food and Drug Administration (FDA) last month granted full approval of the medication. The price of $26,500 per year is steep, but Medicare and Medicaid will probably cover its cost. Mayo Clinic Staff published an online article on June 9, 2023 giving the drug’s possibilities, Lecanemab for Alzheimer’s disease: An option for you?  Here are excerpts: The drug lecanemab appears to slow mental decline in people with early...